RT Journal Article
SR Electronic
T1 Health Economic Burden of COVID-19 in Saudi Arabia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.08.22273439
DO 10.1101/2022.04.08.22273439
A1 Alenzi, Khalidah A.
A1 Al-malky, Hamdan S.
A1 Altebainawi, Ali F.
A1 Abushomi, Hamidah Q.
A1 Alatawi, Fahad O.
A1 Atwadi, Moosa H.
A1 Khobrani, Moosa A.
A1 Almazrou, Dlal A.
A1 Alrubeh, Nariman
A1 Alsoliabi, Zainab A.
A1 Kardam, Abdulaziz M.
A1 Alghamdi, Shakr A.
A1 Alasiri, Abdulrahman
A1 Alshammari, Thamir M.
YR 2022
UL http://medrxiv.org/content/early/2022/04/13/2022.04.08.22273439.abstract
AB Background The coronavirus disease 2019 (COVID-19) pandemic has placed a massive economic burden on health care systems worldwide. Saudi Arabia is one of the numerous countries that have been economically affected by this pandemic. The objective of this study was to provide real-world data on the health economic burden of COVID-19 on the Saudi health sector and assess the direct medical costs associated with the management of COVID-19.Methods A retrospective cohort study was conducted based on data collected from patients hospitalized with COVID-19 across ten institutions in eight different regions in Saudi Arabia. The study calculated the estimated costs of all cases during the study period by using direct medical costs. These costs included costs directly related to medical services, such as the health care treatment, hospital stays, laboratory investigations, treatment, outcome, and other related care.Results A total of 5,286 adult patients admitted with COVID-19 during the study period were included in the study. The average age of the patients was 54 years, and the majority were male. Among the COVID-19 patients hospitalized in a general ward, the median hospital length of stay was 5.5 days (mean: 9.18 days), while the ICU stay was 4.26 days (mean: 7.94 days). The total medical costs for general ward and ICU patients were 14,585,640 SAR and 90,776,250 SAR, respectively. The total laboratory investigations ranked as the highest-cost services (22,086,296 SAR), followed by treatment (14,574,233.1 SAR). Overall, the total cost of all medical services for patients hospitalized with COVID-19 was 193,394,103.1 SAR.Conclusion This national study found that COVID-19 was not only a serious concern for patients but also a serious economic burden on the health care system in Saudi Arabia.Key pointsThe nursing costs and length of stay were lower in the ICU than in the general ward.The costs of hospitalization in general medical wards were less than those of admission to the ICU.These cost data will be valuable for future researchers evaluating the COVID-19 pandemic’s increasing health care economic burden in Saudi Arabia and the implementation of cost-effective models to assess the possible implications of COVID-19 prevention and treatment initiatives.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The central IRB committee at the Saudi ministry of health gave ethical approval for this work IRB20-56EI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.